Compare BYND & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BYND | ANL |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.2M | 350.9M |
| IPO Year | 2018 | 2022 |
| Metric | BYND | ANL |
|---|---|---|
| Price | $0.79 | $9.00 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $1.70 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 30.2M | 244.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $326,452,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.88 |
| 52 Week High | $7.69 | $12.09 |
| Indicator | BYND | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 55.86 |
| Support Level | $0.67 | $1.37 |
| Resistance Level | $0.82 | $10.15 |
| Average True Range (ATR) | 0.08 | 0.93 |
| MACD | 0.01 | -0.37 |
| Stochastic Oscillator | 28.25 | 55.10 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.